| __timestamp | Bausch Health Companies Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6008900000 | 52602000 |
| Thursday, January 1, 2015 | 7853800000 | 105812000 |
| Friday, January 1, 2016 | 7063000000 | 113485000 |
| Sunday, January 1, 2017 | 6176000000 | 285461000 |
| Monday, January 1, 2018 | 6029000000 | 141726000 |
| Tuesday, January 1, 2019 | 6251000000 | 150446000 |
| Wednesday, January 1, 2020 | 5778000000 | 224227000 |
| Friday, January 1, 2021 | 6040000000 | 361897000 |
| Saturday, January 1, 2022 | 5760000000 | 520812000 |
| Sunday, January 1, 2023 | 6198000000 | 636892000 |
| Monday, January 1, 2024 | 855907000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, Bausch Health Companies Inc. and Halozyme Therapeutics, Inc. have shown distinct trajectories in their gross profit over the past decade. From 2014 to 2023, Bausch Health consistently maintained a robust gross profit, peaking in 2015 with a 24% increase from the previous year. Despite fluctuations, their average gross profit remained around $6.3 billion annually.
Conversely, Halozyme Therapeutics, Inc. demonstrated a remarkable growth story. Starting with a modest gross profit in 2014, they achieved a staggering 1,110% increase by 2023. This growth reflects their strategic innovations and market adaptability.
These insights highlight the contrasting strategies and market positions of these two companies, offering valuable lessons in resilience and growth in the pharmaceutical sector.
Key Insights on Gross Profit: AstraZeneca PLC vs Halozyme Therapeutics, Inc.
Key Insights on Gross Profit: Novartis AG vs Bausch Health Companies Inc.
Gross Profit Trends Compared: Amgen Inc. vs Halozyme Therapeutics, Inc.
Gilead Sciences, Inc. and Bausch Health Companies Inc.: A Detailed Gross Profit Analysis
Zoetis Inc. and Bausch Health Companies Inc.: A Detailed Gross Profit Analysis
Exelixis, Inc. and Bausch Health Companies Inc.: A Detailed Gross Profit Analysis
Gross Profit Comparison: Halozyme Therapeutics, Inc. and Perrigo Company plc Trends
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Gross Profit Comparison: Halozyme Therapeutics, Inc. and Evotec SE Trends
Halozyme Therapeutics, Inc. and MiMedx Group, Inc.: A Detailed Gross Profit Analysis
Key Insights on Gross Profit: Bausch Health Companies Inc. vs Taro Pharmaceutical Industries Ltd.
Bausch Health Companies Inc. vs BioCryst Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown